Article

Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging?

Department of Surgery, The Mayo Clinic Arizona, 5777 East Mayo Blvd., Phoenix, AZ 85054, USA.
American journal of surgery (impact factor: 2.36). 10/2009; 198(4):500-4. DOI:10.1016/j.amjsurg.2009.07.012 pp.500-4
Source: PubMed

ABSTRACT In the era of breast conservation therapy, preoperative imaging is imperative in planning a single definitive surgical treatment.
We performed a retrospective review of a prospectively collected database of patients treated at a single institution for invasive breast cancer over 5 years. Clinical and pathologic variables were analyzed with respect to magnetic resonance imaging (MRI) and pathologic tumor size using analysis of variance F tests and chi-square tests.
Of 190 patients, 53% had concordance of MRI and pathologic cancer size within .5 cm. MRI overestimated 33% and underestimated 15% of tumors. Neoadjuvant chemotherapy and lymph node status were associated with discordance. Among tumors overestimated by MRI, 65% had additional significant findings in the breast tissue around the main lesion: satellite lesions, ductal carcinoma in situ, and/or lymphovascular invasion.
Breast MRI is concordant with pathologic tumor size within .5 cm among 53% of patients. Most patients with tumors overestimated by MRI have significant findings in the surrounding breast tissue, the excision of which would be expected to benefit the patient.

0 0
 · 
0 Bookmarks
 · 
35 Views
  • Source
    Article: Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.
    A Fangberget, L B Nilsen, K H Hole, M M Holmen, O Engebraaten, B Naume, H-J Smith, D R Olsen, T Seierstad
    [show abstract] [hide abstract]
    ABSTRACT: To explore the predictive value of MRI parameters and tumour characteristics before neoadjuvant chemotherapy (NAC) and to compare changes in tumour size and tumour apparent diffusion coefficient (ADC) during treatment, between patients who achieved pathological complete response (pCR) and those who did not. Approval by the Regional Ethics Committee and written informed consent were obtained. Thirty-one patients with invasive breast carcinoma scheduled for NAC were enrolled (mean age, 50.7; range, 37-72). Study design included MRI before treatment (Tp0), after four cycles of NAC (Tp1) and before surgery (Tp2). Data in pCR versus non-pCR groups were compared and cut-off values for pCR prediction were evaluated. Before NAC, HER2 overexpression was the single significant predictor of pCR (p = 0.006). At Tp1 ADC, tumour size and changes in tumour size were all significantly different in the pCR and non-pCR groups. Using 1.42 × 10(-3) mm(2)/s as the cut-off value for ADC, pCR was predicted with sensitivity and specificity of 88% and 80%, respectively. Using a cut-off value of 83% for tumour volume reduction, sensitivity and specificity for pCR were 91% and 80%. ADC, tumour size and tumour size reduction at Tp1 were strong independent predictors of pCR.
    European Radiology 12/2010; 21(6):1188-99. · 3.22 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

breast conservation therapy
 
Breast MRI
 
breast tissue
 
invasive breast cancer
 
lymph node status
 
lymphovascular invasion
 
magnetic resonance imaging
 
MRI overestimated 33%
 
Neoadjuvant chemotherapy
 
pathologic cancer size
 
pathologic tumor size
 
pathologic variables
 
preoperative imaging
 
satellite lesions
 
single definitive surgical treatment
 
single institution
 
surrounding breast tissue
 
tumors
 
tumors overestimated
 
variance F tests